| Authors: |
Burleson SCM; Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA., Freebern WJ; Bristol-Myers Squibb Company, Immunotoxicology, New Brunswick, NJ, USA., Burleson FG; Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA., Burleson GR; Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA., Johnson VJ; Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA., Luebke RW; United States Environmental Protection Agency, Cardiopulmonary and Immunotoxicology Branch, Environmental Public Health Division, National Health and Environmental Effects Laboratory, Office of Research and Development, Research Triangle Park, NC, USA.; Burleson Research Technologies, Inc., Morrisville, NC, USA. |
